| __timestamp | Halozyme Therapeutics, Inc. | Insmed Incorporated |
|---|---|---|
| Wednesday, January 1, 2014 | 35942000 | 31073000 |
| Thursday, January 1, 2015 | 40028000 | 43216000 |
| Friday, January 1, 2016 | 45853000 | 50679000 |
| Sunday, January 1, 2017 | 53816000 | 79171000 |
| Monday, January 1, 2018 | 60804000 | 168218000 |
| Tuesday, January 1, 2019 | 77252000 | 210796000 |
| Wednesday, January 1, 2020 | 45736000 | 203613000 |
| Friday, January 1, 2021 | 50323000 | 234273000 |
| Saturday, January 1, 2022 | 143526000 | 265784000 |
| Sunday, January 1, 2023 | 149182000 | 344501000 |
| Monday, January 1, 2024 | 154335000 |
Igniting the spark of knowledge
In the competitive landscape of biotechnology, understanding financial trends is crucial. Over the past decade, Insmed Incorporated and Halozyme Therapeutics, Inc. have shown distinct trajectories in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Insmed's SG&A expenses surged by over 1,000%, reflecting its aggressive expansion and investment in operational capabilities. In contrast, Halozyme's expenses grew by approximately 315%, indicating a more measured approach. Notably, in 2023, Insmed's SG&A expenses were nearly 2.3 times higher than Halozyme's, highlighting its significant financial commitment to growth. This divergence in spending strategies may offer insights into each company's market positioning and future potential. As the biotech sector continues to evolve, these financial patterns could be pivotal in shaping investor perceptions and strategic decisions.
Who Optimizes SG&A Costs Better? AstraZeneca PLC or Insmed Incorporated
SG&A Efficiency Analysis: Comparing GSK plc and Insmed Incorporated
SG&A Efficiency Analysis: Comparing Viatris Inc. and Halozyme Therapeutics, Inc.
Breaking Down SG&A Expenses: Insmed Incorporated vs Sarepta Therapeutics, Inc.
Insmed Incorporated and Corcept Therapeutics Incorporated: SG&A Spending Patterns Compared
Insmed Incorporated or Viking Therapeutics, Inc.: Who Manages SG&A Costs Better?
Breaking Down SG&A Expenses: Insmed Incorporated vs Dynavax Technologies Corporation
Who Optimizes SG&A Costs Better? Insmed Incorporated or Galapagos NV
Halozyme Therapeutics, Inc. and Apellis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
Halozyme Therapeutics, Inc. or ADMA Biologics, Inc.: Who Manages SG&A Costs Better?
Halozyme Therapeutics, Inc. or CRISPR Therapeutics AG: Who Manages SG&A Costs Better?
Selling, General, and Administrative Costs: Halozyme Therapeutics, Inc. vs Bausch Health Companies Inc.